Orum Therapeutics Presents Preclinical Data at AACR 2022 Highlighting Novel Dual-Precision Targeted Protein Degrader, ORM-5029, Degrading GSPT1
BOSTON & DAEJEON, South Korea--(BUSINESS WIRE)--#AACR22--Orum Therapeutics, a private biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs),...







